X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MDX-1097 (kappamab) targets a receptor called Kappa Myeloma Antigen (KMA) found only on the surface of myeloma cells in in combination with lenalidomide and dexamethasone in kappa-type multiple myeloma patients who had relapsed or become refractory to other treatment options.
Lead Product(s): KappaMab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: MDX-1097
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Anti-KMA CAR-T is a myeloma-specific antigen not found on normal cells. It has completed preclinical studies and is being developed to treat kappa-type multiple myeloma.
Lead Product(s): Anti-KMA CAR-T Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
The funds raised under the placement will directly support manufacturing of the next batch of the Kappa antibody, MDX-1097 plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.
Lead Product(s): KappaMab,Dexamethasone,Lenalidomide
Therapeutic Area: Oncology Product Name: MDX-1097
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Platinum International Health Care Fund
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
